Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in the treatment of new-onset juvenile dermatomyositis: a phase II trial
2022-000506-10Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of baricitinib in juvenile dermatomyositis (JDM), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: PRINTO 20 level of improvement at week 24. Started Apr 2022; status: active.
02
Drugs
baricitinib
03
Conditions
juvenile dermatomyositis (JDM)
Beyond the preview
Go deeper on 2022-000506-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000506-10.